Incidence and prophylaxis of herpes zoster in relapsed or refractory B-cell lymphoma patients after CD19-specific CAR-T cell therapy

Leuk Lymphoma. 2022 Apr;63(4):1001-1004. doi: 10.1080/10428194.2021.2010062. Epub 2021 Nov 28.

Authors

Hui Liu¹, Ping Li², Aiqi Zhao¹, Wen Lei¹, Aibin Liang², Wenbin Qian^{1

3

4}

Affiliations

¹ Department of Hematology, the Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, People's Republic of China.
² Department of Hematology, Tongji Hospital of Tongji University, Shanghai, People's Republic of China.
³ Institute of Hematology, Zhejiang University, Hangzhou, People's Republic of China.
⁴ National Clinical Research Center for Hematologic Diseases, the First Affiliated Hospital of Soochow University.

PMID: 34842037
DOI: 10.1080/10428194.2021.2010062

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antigens, CD19
Cell- and Tissue-Based Therapy
Herpes Zoster* / epidemiology
Herpes Zoster* / etiology
Herpes Zoster* / prevention & control
Humans
Immunotherapy, Adoptive / adverse effects
Incidence
Lymphoma, B-Cell* / etiology
Lymphoma, B-Cell* / therapy
Receptors, Chimeric Antigen*

Substances

Antigens, CD19
Receptors, Chimeric Antigen